Statins in the Elderly

Statins are HMG-CoA reductase inhibitors — they block the rate-limiting step of hepatic cholesterol synthesis, upregulate LDL receptors, and lower LDL-C by 20–55%.

Pleiotropic effects matter as much as lipid lowering: statins stabilise vulnerable atherosclerotic plaque by reducing lipid content, minimising inflammation, and improving endothelial function.

Three out of four acute myocardial infarcts are thought to result from rupture or erosion of such vulnerable plaque.

High-intensity statin therapy reduces LDL-C by 50–55%; moderate intensity by about 30–49%.

A meta-analysis of 28 randomised controlled trials showed significant benefit of statins for secondary prevention in all age groups, including patients over 75 (Cholesterol Treatment Trialists’ Collaboration, Lancet 2019).

Relative risk reduction of major vascular events per 1 mmol/l LDL-C reduction in those over 75 was 26% — at least as good as in younger patients.

Key trials in the elderly: PROSPER (age 70–82, pravastatin 40 mg, RR 0.85 for cardiovascular events); HPS (up to age 80, simvastatin 40 mg, RR 0.76 for major vascular events, RR 0.87 for all-cause death); LIPS (fluvastatin 80 mg after first PCI, RR 0.78 for MACE).

ACC/AHA guidance — in patients over 75 with clinical ASCVD it is reasonable to initiate moderate- or high-intensity statin therapy after considering risk reduction, adverse effects, drug interactions, frailty and patient preference.

Moderate-intensity statin may be preferable in older adults because of higher adverse event rates, lower adherence, and higher discontinuation with high-intensity therapy.

Secondary prevention treatment thresholds: ACC/AHA and Canadian guidelines use LDL-C >70 mg/dl or non-HDL-C >100 mg/dl; ESC/EAS set an “ideal” target of LDL-C <55 mg/dl and non-HDL-C <85 mg/dl. PRIMARY PREVENTION — WEAK AND CONFLICTING EVIDENCE

Clinical trial data demonstrating statin benefit for primary prevention are not available for adults older than 75.

In the primary prevention subgroup of PROSPER (56% of participants), pravastatin showed no significant reduction in coronary death, non-fatal MI, or stroke over 3.2 years.

ALLHAT-LLT post hoc analysis found no benefit of pravastatin for primary prevention in those aged 75 and over, with a non-significant trend toward increased all-cause mortality.

In a well-characterised cohort aged 75 and over, LDL-C ≥130 mg/dl was not associated with increased 5-year ASCVD event rates.

In the meta-analysis of statins by age, there was no significant benefit among patients older than 70 for primary prevention, with a trend toward smaller proportional risk reduction with increasing age.

ACC/AHA states it “may be reasonable” to start moderate-intensity statin in adults ≥75 with LDL-C between 70 and 189 mg/dl — but equally, it may be reasonable not to. ESC/EAS says it “may be considered” if high risk, such as diabetes.

EWTOPIA 75 (open-label, ezetimibe, entry LDL-C ≥140 mg/dl) is the main primary-prevention trial in this age group and carries considerable weight in meta-analyses.

Retrospective data show statins for primary prevention in those aged 75–84 with type 2 diabetes reduced cardiovascular events by 24% and all-cause mortality by 16%.

Adverse effects: muscle aches, rhabdomyolysis, deranged liver function, possible increase in type 2 diabetes, and concerns about cognitive dysfunction.

Adherence is poor — only about one in four older people is still taking a statin two years after prescription, and about 20% show “primary non-adherence”, never starting at all.

Time to benefit for statins in primary prevention is at least two years — so life expectancy, lag time to benefit, and the therapeutic horizon must be weighed against competing mortality and polypharmacy.

The decision in adults 75 or older should be made through a tailored, shared decision-making approach balancing benefit, harm, and patient values.